Predicting risk of immune therapy side effects
Part of Cancer, Immune system & allergy clinical trials.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be planning standard-of-care immune checkpoint (ICI) treatment for a solid tumor, based on FDA labeling or major guidelines (not another research trial).
- If you had ICI before, you must have finished it at least 180 days before starting this study, and you must not have stopped it earlier because of immune-related side effects.
- You must not have had chemotherapy, biologic, or targeted therapy in the last 21 days before you register.
- Any past treatment side effects should be mostly gone (about mild or moderate limits), and your clinician must feel you have recovered enough to safely start the planned ICI treatment.
- You must be able and willing to complete questionnaires (in English, Spanish, or French), including before starting treatment, and you must be willing to do the follow-up data collection.
- You must be 18 or older, complete your check-up paperwork and physical exam within 28 days before registration, and be willing to consider optional specimen banking.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood, stool, and tissue samples from people who have had side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer). It aims to learn more about these side effects, so doctors can better manage them in the future.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study is a registry that collects information on immune-related side effects in cancer patients receiving immunotherapy. It helps doctors understand and manage these side effects better.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
Hear when a new Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.